MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm15041486

Медицинская библиотека · Journal of clinical medicine · 2026

Association of IL7 rs16906115 Polymorphism with Immune-Related Adverse Events in Patients with Advanced Lung Cancer Undergoing Immunotherapy.

González-Hernández Andrea, Paz-López Guillermo, Martínez-Gálvez Beatriz, Paniagua Felipe Vaca, Barragán Isabel, Pérez-Ruiz Elisabeth, Benitez José Carlos, Rueda-Dominguez Antonio, Oliver Javier

СтатьяПеревод в очереди

Аннотация

Background

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (aNSCLC). However, immune-related adverse events (irAEs) remain a clinical challenge in this context. Genetic variants acting as cis-eQTLs may predict toxicity risk, thereby enabling personalized treatment. Specifically, the interleukin 7 (IL7) rs16906115 variant has recently been implicated in ICI-related toxicity in other malignancies, like melanoma, although its role in lung cancer remains less defined. We investigated the association between the IL7 rs16906115 polymorphism, immune-related adverse events (irAEs), and survival outcomes in patients with aNSCLC receiving ICIs.

Methods

This retrospective cohort study analyzed 153 patients with aNSCLC treated with ICIs (2018-2023) at two centers in Spain. The final analytical cohort included 124 patients with complete clinical follow-up. IL7 rs16906115 genotyping was performed using TaqMan assays. Associations between genotypes/alleles, irAEs, and survival (PFS/OS) were evaluated using logistic regression and Kaplan-Meier analysis. A clinical-genetic predictive model was developed.

Results

The A allele frequency was 8.5%. Carriers of the A allele (AG/AA genotypes) had significantly higher irAEs rates compared to GG homozygotes (OR = 3.77, 95% CI: 1.16-12.6, p = 0.0081). The association remained significant after multivariable adjustment (OR = 4.64, 95% CI: 1.50-17.2, p = 0.0203). Crucially, A-allele carriers exhibited significantly shorter Progression-Free Survival compared to non-carriers (median 6.6 vs. 10 months, p = 0.0029). The combined clinical-genetic model achieved moderate predictive performance for toxicity (AUC = 0.67, 95% CI: 0.56-0.78) compared to clinical-only models (AUC = 0.57), stratifying patients into moderate- and high-risk groups, respectively.

Conclusions

The IL7 rs16906115 polymorphism is a potential pharmacogenetic biomarker for predicting adverse events in aNSCLC immunotherapy. These findings identify the IL7 rs16906115 polymorphism as a candidate biomarker, suggesting its potential utility as an exploratory tool for risk stratification that warrants further validation.

Для цитирования: González-Hernández Andrea, Paz-López Guillermo, Martínez-Gálvez Beatriz, Paniagua Felipe Vaca, Barragán Isabel, Pérez-Ruiz Elisabeth, Benitez José Carlos, Rueda-Dominguez Antonio, Oliver Javier. Association of IL7 rs16906115 Polymorphism with Immune-Related Adverse Events in Patients with Advanced Lung Cancer Undergoing Immunotherapy.. Journal of clinical medicine. 2026. DOI: 10.3390/jcm15041486.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.